What is Non-HDL-C?
Non-HDL-C (non-high-density lipoprotein cholesterol) is calculated by subtracting HDL cholesterol from total cholesterol (Total Cholesterol - HDL-C), and it represents the cholesterol content of all atherogenic (plaque-forming) lipoproteins in the blood. 1, 2, 3
Composition and Clinical Significance
Non-HDL-C captures the cholesterol carried in all apolipoprotein B-containing lipoproteins, which includes:
- LDL (low-density lipoprotein) - the primary atherogenic particle
- VLDL (very low-density lipoprotein) - triglyceride-rich particles
- IDL (intermediate-density lipoprotein) - remnant particles
- Lipoprotein(a) - an independent cardiovascular risk factor
This comprehensive measurement makes non-HDL-C particularly valuable because it accounts for all cholesterol in atherogenic particles, not just LDL-C alone. Non-HDL-C is an independent predictor of cardiovascular events and, in many studies, has proven to be a stronger predictor than LDL-C alone. 1, 4, 5
Key Advantages Over LDL-C
No Fasting Required
Unlike calculated LDL-C, non-HDL-C can be accurately measured in non-fasting samples, making it more practical for routine clinical use 6, 2, 4, 7. This is particularly important since LDL-C calculations using the Friedewald equation become unreliable when triglycerides exceed 400 mg/dL (4.5 mmol/L) 2.
Superior in Hypertriglyceridemia
Non-HDL-C is especially useful when triglyceride levels are elevated (>150-200 mg/dL) because at these levels, cholesterol in LDL particles is replaced by triglyceride, making LDL-C an unreliable indicator of actual atherogenic particle burden 6, 7, 8. The measurement captures the increased cardiovascular risk from triglyceride-rich remnant particles that accumulate in these conditions 1, 8.
No Additional Cost
Non-HDL-C requires no additional laboratory testing or expense—it's derived from the standard lipid panel that measures total cholesterol and HDL-C 6, 4, 7.
Treatment Targets
Non-HDL-C goals are set 30 mg/dL (0.8 mmol/L) higher than corresponding LDL-C goals across all risk categories 1, 2, 9. This 30 mg/dL difference represents the normal contribution of VLDL cholesterol to the total non-HDL-C concentration 1, 4.
For example:
- If LDL-C goal is <100 mg/dL → Non-HDL-C goal is <130 mg/dL
- If LDL-C goal is <70 mg/dL → Non-HDL-C goal is <100 mg/dL
Role in Clinical Guidelines
Non-HDL-C serves as a secondary treatment target when triglycerides are ≥200 mg/dL after LDL-C goals have been achieved according to ATP III guidelines 1, 9, 4. More recent guidelines have elevated its status further, with the 2021 Canadian guidelines and 2026 ACC/AHA guidelines recognizing non-HDL-C as an alternate primary target alongside LDL-C 7, 10.
The 2022 ACC Expert Consensus includes non-HDL-C thresholds as factors to consider when deciding whether to add nonstatin therapies, emphasizing that non-HDL-C represents all potentially atherogenic particles and correlates strongly with apolipoprotein B 11.
Clinical Context
Non-HDL-C is particularly valuable in patients with:
- Metabolic syndrome - where atherogenic dyslipidemia is common 1
- Type 2 diabetes - characterized by elevated triglycerides and low HDL-C 4, 8
- Hypertriglyceridemia (150-500 mg/dL range) - where remnant particles accumulate 1, 8
In adolescents with diabetes, elevated non-HDL-C correlates with poorer glycemic control (higher HbA1c) and higher BMI, making it a useful screening tool in this population 12.
Important Caveat
While non-HDL-C is highly useful in most clinical scenarios, one study in hemodialysis patients suggested it may not adequately capture the specific lipoprotein abnormalities in end-stage renal disease 13. However, this represents a specialized population where standard lipid metrics may require different interpretation.